NCT06683690 TGF β 1 Expression Related Gene Polymorphism
| NCT ID | NCT06683690 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aswan University |
| Condition | Leprosy |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-07-10 |
| Primary Completion | 2025-07-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-07-10 with a primary completion date of 2025-07-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Leprosy is one of the oldest human infectious diseases. It is a chronic infectious contagious, granulomatous disease caused by intracellular bacillus. Mycobacterium leprae, this chronic granulomatous disease presents symptoms that mainly affected the skin, the nervous system and the reticuloendothelial system, also other systems can be affected, such as the upper respiratory tract, bones and joints, eyes and adrenal glands. TGF- β is a pleiotropic cytokine that employs several functions on different types of cells. The effect of other cytokines may finally modulate the cellular response in the presence of TGF- β, causing a different effect depending on the activation state of the cell involved. In addition, TGF- β promotes the healing of inflamed tissue through the stimulation and regulation of extracellular matrix by fibroblasts, in addition to inducing the proliferation of endothelial cells required for angiogenesis. Thus, TGF- β is able to regulate the expression of other growth factors, increasing their level of activity.
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes with leprosy. * Age above 18 years. * patients on multidrug therapy of leprosy. Exclusion Criteria: * Patients with other dermatological disease. * Patients with leprosy reaction. * Pregnancy and lactation. * Patients with autoimmune disease.
Contact & Investigator
Moustafa Adam Ali El Taieb, Professor
STUDY CHAIR
Dermatology, Venereology and Andrology. Faculty of Medicine, Aswan University
Frequently Asked Questions
Who can join the NCT06683690 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Leprosy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06683690 currently recruiting?
Yes, NCT06683690 is actively recruiting participants. Contact the research team at gehada022@gmail.com for enrollment information.
Where is the NCT06683690 trial being conducted?
This trial is being conducted at Aswān, Egypt.
Who is sponsoring the NCT06683690 clinical trial?
NCT06683690 is sponsored by Aswan University. The principal investigator is Moustafa Adam Ali El Taieb, Professor at Dermatology, Venereology and Andrology. Faculty of Medicine, Aswan University. The trial plans to enroll 60 participants.